<DOC>
	<DOCNO>NCT00048568</DOCNO>
	<brief_summary>Short Term : The purpose clinical research study learn abatacept ( BMS-188667 ) combination methotrexate well methotrexate alone participant active rheumatoid arthritis respond methotrexate . The safety treatment also study . Long Term Extension : The purpose amendment provide participant complete initial 12-month double-blind treatment period opportunity receive open label treatment active drug treatment abatacept approved local country clinical development discontinue .</brief_summary>
	<brief_title>A Phase III Study Abatacept ( BMS-188667 ) Patients With Active Rheumatoid Arthritis Inadequate Response Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Rheumatoid Arthritis ( RA ) great 1 year time initial diagnosis RA . Participants must take methotrexate least 3 month least weekly dose 15 mg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>